{"id":257279,"date":"2025-11-07T09:50:26","date_gmt":"2025-11-07T08:50:26","guid":{"rendered":"https:\/\/r3i.org\/focus-elevated-lipoproteina-a-risk-enhancer-in-peripheral-artery-disease\/"},"modified":"2026-03-04T21:28:00","modified_gmt":"2026-03-04T20:28:00","slug":"focus-elevated-lipoproteina-a-risk-enhancer-in-peripheral-artery-disease","status":"publish","type":"page","link":"https:\/\/r3i.org\/ja\/focus-elevated-lipoproteina-a-risk-enhancer-in-peripheral-artery-disease\/","title":{"rendered":"Focus \u2013 Elevated lipoprotein(a): a risk enhancer in peripheral artery disease"},"content":{"rendered":"

[et_pb_section fb_built=”1″ _builder_version=”4.27.4″ _module_preset=”default” custom_padding=”1px|||||” global_colors_info=”{}”][et_pb_row _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” header_2_text_color=”gcid-primary-color” header_5_text_color=”gcid-secondary-color” text_orientation=”center” width=”99%” custom_margin=”|-147px||||” custom_padding=”|0px||||” hover_enabled=”0″ global_colors_info=”{%22gcid-primary-color%22:%91%22quote_text_color%22,%22quote_text_color%22,%22quote_text_color%22,%22header_2_text_color%22%93,%22gcid-secondary-color%22:%91%22header_5_text_color%22%93}” sticky_enabled=”0″]<\/p>\n

\u30ea\u30dd\u30bf\u30f3\u30d1\u30af\u8cea(a)\u306e\u4e0a\u6607\uff1a\u672b\u68a2\u52d5\u8108\u75be\u60a3\u306b\u304a\u3051\u308b\u30ea\u30b9\u30af\u5897\u5f37\u56e0\u5b50<\/h2>\n

2025\u5e7410\u6708
<\/span><\/h5>\n

Mass General Brigham\uff08MGB\uff09\u306eLp(a)\u30ec\u30b8\u30b9\u30c8\u30ea\u306e\u7d50\u679c\u3067\u306f\u3001\u30ea\u30dd\u30bf\u30f3\u30d1\u30af\u8cea(a)\u306e\u4e0a\u6607\u304c\u5fc3\u8840\u7ba1\u30a4\u30d9\u30f3\u30c8\u304a\u3088\u3073\u4e0b\u80a2\u306e\u6709\u5bb3\u4e8b\u8c61\u306e\u4e21\u65b9\u3068\u5f37\u304f\u95a2\u9023\u3057\u3066\u3044\u308b\u3053\u3068\u304c\u793a\u3055\u308c\u307e\u3057\u305f\u3002<\/em><\/p>\n

McClintick DJ, Biery DW, Berman AN, et al. Association between lipoprotein(a) and cardiovascular events in patients with peripheral artery disease: the Mass General Brigham Lp(a) registry. Eur J Prevent Cardiol 2025; https:\/\/doi.org\/10.1093\/eurjpc\/zwaf475<\/a> <\/em><\/p>\n

\u7814\u7a76\u6982\u8981<\/strong><\/p>\n\n\n\n\n\n\n\n
\n

\u76ee\u7684<\/strong><\/p>\n<\/td>\n

\n

\u30d9\u30fc\u30b9\u30e9\u30a4\u30f3\u6642\u306e\u672b\u68a2\u52d5\u8108\u75be\u60a3\uff08PAD\uff09\u60a3\u8005\u306b\u304a\u3044\u3066\u3001\u30ea\u30dd\u86cb\u767d\uff08a\uff09\uff3bLp\uff08a\uff09\uff3d\u3068\u4e3b\u8981\u6709\u5bb3\u5fc3\u8840\u7ba1\u30a4\u30d9\u30f3\u30c8\uff08MACE\uff09\u304a\u3088\u3073\u4e3b\u8981\u6025\u6027\u4e0b\u80a2\u30a4\u30d9\u30f3\u30c8\uff08MALE\uff09\u3068\u306e\u95a2\u9023\u3092\u691c\u8a0e\u3059\u308b\u3053\u3068\u3002 <\/p>\n

 <\/p>\n<\/td>\n

\n

 <\/p>\n<\/td>\n<\/tr>\n

\n

\u7814\u7a76\u30c7\u30b6\u30a4\u30f3<\/strong><\/p>\n<\/td>\n

\n

\u767b\u9332Mass General Brigham Lp(a)\u30ec\u30b8\u30b9\u30c8\u30ea\u306f\u30012000\u5e74\u304b\u30892019\u5e74\u307e\u3067\u7c73\u56fd\u306e2\u3064\u306e3\u6b21\u533b\u7642\u30bb\u30f3\u30bf\u30fc\u3067Lp(a)\u3092\u6e2c\u5b9a\u3057\u305f\u4eba\u3092\u5bfe\u8c61\u3068\u3057\u305f\u3002<\/p>\n

 <\/p>\n<\/td>\n

\n

 <\/p>\n<\/td>\n<\/tr>\n

\n

\u7814\u7a76\u5bfe\u8c61\u8005 <\/strong><\/p>\n<\/td>\n

\n

\u3053\u306e\u767b\u9332\u306b\u306f21,410\u4f8b\u306e\u60a3\u8005\u304c\u767b\u9332\u3055\u308c\u3001\u305d\u306e\u3046\u30613757\u4f8b\u304cPAD\u3067\u3042\u3063\u305f\uff08\u5973\u602739\uff05\u3001\u5e74\u9f62\u4e2d\u592e\u502468\u6b73\uff09\u3002PAD\u60a3\u8005\u306e81\uff05\u304c\u8102\u8cea\u7570\u5e38\u75c7\u3067\u3042\u308a\u3001\u30b9\u30bf\u30c1\u30f3\u306b\u3088\u308b\u6cbb\u7642\u3092\u53d7\u3051\u3066\u3044\u305f\u3002 <\/p>\n

 <\/p>\n<\/td>\n

\n

 <\/p>\n<\/td>\n<\/tr>\n

\n

\u4e3b\u306a\u7814\u7a76\u5909\u6570<\/strong><\/p>\n

<\/strong><\/p>\n<\/td>\n

\n

– MACE\uff08\u5fc3\u8840\u7ba1\u6b7b\u3001\u975e\u81f4\u6b7b\u7684\u5fc3\u7b4b\u6897\u585e\uff08MI\uff09\u3001\u51a0\u52d5\u8108\u8840\u884c\u518d\u5efa\u8853\u306e\u8907\u5408\uff09\u3002<\/p>\n

– \u7537\u6027\u3001\u8840\u7ba1\u5185\u6cbb\u7642\u307e\u305f\u306f\u5916\u79d1\u7684\u672b\u68a2\u8840\u884c\u518d\u5efa\u8853\u3001\u6025\u6027\u56db\u80a2\u865a\u8840\u3001\u5927\u4e0b\u80a2\u5207\u65ad\u306e\u8907\u5408\u3002<\/p>\n

 <\/p>\n<\/td>\n

\n

 <\/p>\n<\/td>\n<\/tr>\n

\n

\u65b9\u6cd5<\/strong><\/p>\n<\/td>\n

\n

\u60a3\u8005\u306fLp(a)\u30d1\u30fc\u30bb\u30f3\u30bf\u30a4\u30eb\u306b\u57fa\u3065\u3044\u3066\u56db\u5206\u4f4d\u7fa4\u306b\u5206\u985e\u3055\u308c\u305f\uff1a\u56db\u5206\u4f4d\u7fa41\u3001\u7b2c1<\/sup>\uff5e25\u4f4d<\/sup>\u3001Lp(a)\u226614nmol\/L\u3001\u56db\u5206\u4f4d\u7fa42\u3001\u7b2c26<\/sup>\uff5e50<\/sup>\u4f4d\u3001Lp(a)14-<42nmol\/L\u3001\u56db\u5206\u4f4d\u7fa43\u3001\u7b2c51<\/sup>\uff5e75<\/sup>\u4f4d\u3001Lp(a)42-<132nmol\/L\u3001\u56db\u5206\u4f4d\u7fa44\u3001\u7b2c76<\/sup>\uff5e100<\/sup>\u4f4d\u3001Lp(a)132-855nmol\/L\u3002Lp(a)\u3068MACE\u304a\u3088\u3073MALE\u306e\u30ea\u30b9\u30af\u3068\u306e\u95a2\u9023\u3092\u8a55\u4fa1\u3059\u308b\u305f\u3081\u306b\u3001\u5f93\u6765\u306e\u5371\u967a\u56e0\u5b50\u3067\u8abf\u6574\u3057\u305f\u5f8c\u306eCox\u6bd4\u4f8b\u30cf\u30b6\u30fc\u30c9\u30e2\u30c7\u30ea\u30f3\u30b0\u304c\u7528\u3044\u3089\u308c\u305f\u3002 <\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n\n\n\n\n
\n

\u7d50\u679c<\/strong><\/p>\n<\/td>\n

\n

\u8ffd\u8de1\u671f\u9593\u4e2d\u592e\u502415.1\u5e74\uff08\u56db\u5206\u4f4d\u7bc4\u56f2[IQR]13.9-16.1\uff09\u306e\u9593\u306b\u3001\u60a3\u8005\u306e12\uff05\uff08n=447\uff09\u304c\u975e\u81f4\u6b7b\u7684MI\u3092\u7d4c\u9a13\u3057\u300114\uff05\uff08n=516\uff09\u304c\u51a0\u52d5\u8108\u8840\u884c\u518d\u5efa\u8853\u3092\u53d7\u3051\u300124\uff05\uff08n=904\uff09\u304c\u5fc3\u8840\u7ba1\u7cfb\u306e\u539f\u56e0\u3067\u6b7b\u4ea1\u3057\u305f\u3002\u6700\u521d\u306eLp(a)\u56db\u5206\u4f4d\u7fa4\uff08\u57fa\u6e96\uff09\u306e\u60a3\u8005\u3068\u6bd4\u8f03\u3059\u308b\u3068\u3001Lp(a)\u6700\u9ad8\u56db\u5206\u4f4d\u7fa4\u306e\u60a3\u8005\u306fMACE\u306e\u30cf\u30b6\u30fc\u30c9\u304c36\uff05\u9ad8\u304b\u3063\u305f\uff08p<0.001\u3001\u672a\u8abf\u6574\u30cf\u30b6\u30fc\u30c9\uff09\u3002\u3053\u308c\u3089\u306e\u6240\u898b\u306f\u8abf\u6574\u5f8c\u3082\u5f37\u56fa\u3067\u3042\u308a\u3001MACE\u306e\u30ea\u30b9\u30af\u306f30\uff05\u9ad8\u304b\u3063\u305f\uff08\u8abf\u6574\u5f8c\u30cf\u30b6\u30fc\u30c9\u6bd41.30\u300195\uff05\u4fe1\u983c\u533a\u95931.12-1.50\u3001p=0.001\uff09\u3002\u56db\u5206\u4f4d\u7fa43\uff0842-<132 nmol\/L\uff09\u306e\u60a3\u8005\u306b\u304a\u3044\u3066\u3082\u3001MACE\u767a\u75c7\u30ea\u30b9\u30af\u306f24\uff05\u5897\u52a0\u3057\u305f\uff08\u88dc\u6b63\u5f8c\u30cf\u30b6\u30fc\u30c9\u6bd41.30\u300195\uff05CI 1.07-1.45\u3001p=0.005\uff09\u3002\u500b\u3005\u306e\u30a8\u30f3\u30c9\u30dd\u30a4\u30f3\u30c8\u306b\u95a2\u3057\u3066\u306f\u3001Lp(a)\u304c\u6700\u3082\u9ad8\u3044\u56db\u5206\u4f4d\u7fa4\u306e\u60a3\u8005\u306f\u56db\u5206\u4f4d\u7fa41\u306e\u60a3\u8005\u3068\u6bd4\u8f03\u3057\u3066\u3001MI\u306e\u88dc\u6b63\u5f8c\u30cf\u30b6\u30fc\u30c9\u304c45\uff05\u9ad8\u304f\uff08p=0.004\uff09\u3001\u51a0\u52d5\u8108\u8840\u884c\u518d\u5efa\u8853\u306e\u30cf\u30b6\u30fc\u30c9\u304c68\uff05\u9ad8\u304b\u3063\u305f\uff08p< 0.001\uff09\u3002 <\/p>\n

\u540c\u3058\u8ffd\u8de1\u671f\u9593\u4e2d\u306b\u3001\u60a3\u8005\u306e9\uff05\uff08n=355\uff09\u304c\u6025\u6027\u56db\u80a2\u865a\u8840\u3092\u7d4c\u9a13\u3057\u300124\uff05\uff08n=919\uff09\u304c\u672b\u68a2\u8840\u884c\u518d\u5efa\u8853\u3092\u53d7\u3051\u30012.4\uff05\uff08n=90\uff09\u304c\u4e3b\u8981\u306a\u4e0b\u80a2\u5207\u65ad\u8853\u3092\u53d7\u3051\u305f\u3002\u7b2c4\u56db\u5206\u4f4d\u7fa4\u306e\u60a3\u8005\u306f\u3001\u7b2c1\u56db\u5206\u4f4d\u7fa4\u306e\u60a3\u8005\u3068\u6bd4\u8f03\u3057\u3066\u3001\u672b\u68a2\u8840\u884c\u518d\u5efa\u8853\u306e\u30cf\u30b6\u30fc\u30c9\u304c20\uff05\u9ad8\u3044\uff08p=0.045\uff09\u3053\u3068\u3092\u542b\u3081\u3001MALE\u30ea\u30b9\u30af\u304c19\uff05\u9ad8\u304b\u3063\u305f\uff08\u88dc\u6b63\u30cf\u30b6\u30fc\u30c9\u6bd41.19\u300195\uff05CI 1.01-1.40\u3001p=0.043\uff09\u3002 <\/p>\n

 <\/p>\n<\/td>\n<\/tr>\n

\n

\u8457\u8005\u7d50\u8ad6<\/strong><\/p>\n<\/td>\n

\n

PAD\u60a3\u8005\u306b\u304a\u3051\u308bLp(a)\u306e\u4e0a\u6607\u306f\u3001MACE\u3068MALE\u4e21\u65b9\u306e\u30ea\u30b9\u30af\u4e0a\u6607\u3068\u95a2\u9023\u3057\u3066\u3044\u305f\u3002\u3057\u305f\u304c\u3063\u3066\uff0cLp(a)\u306e\u6e2c\u5b9a\u306f\u91cd\u8981\u306a\u4e88\u5f8c\u4e88\u6e2c\u56e0\u5b50\u3067\u3042\u308a\uff0c\u3053\u306e\u9ad8\u30ea\u30b9\u30af\u96c6\u56e3\u306b\u304a\u3051\u308b\u3055\u3089\u306a\u308b\u30ea\u30b9\u30af\u5c64\u5225\u5316\u3092\u53ef\u80fd\u306b\u3059\u308b\u304b\u3082\u3057\u308c\u306a\u3044\u3002 <\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u30b3\u30e1\u30f3\u30c8<\/strong><\/p>\n

Lp(a)\u306e\u4e0a\u6607\u306f\u3001PAD\u3092\u542b\u3080\u52d5\u8108\u786c\u5316\u6027\u5fc3\u8840\u7ba1\u7cfb\u75be\u60a3\u306e\u5371\u967a\u56e0\u5b50\u3068\u3057\u3066\u8a8d\u8b58\u3055\u308c\u3066\u3044\u308b(1)\u3002\u73fe\u5728\u306e\u30ac\u30a4\u30c9\u30e9\u30a4\u30f3\u3067\u306f\u3001Lp(a)\u306e\u4e0a\u6607\u306f\u30ea\u30b9\u30af\u5897\u5f37\u56e0\u5b50\u3067\u3042\u308a\u3001\u9ad8\u30ea\u30b9\u30af\u60a3\u8005\u306b\u304a\u3051\u308b\u6b8b\u5b58\u5371\u967a\u56e0\u5b50\u3067\u3042\u308b\u3068\u3055\u308c\u3066\u3044\u308b(2,3)\u3002Lp(a)\u3068PAD\u304cMACE\u306e\u5371\u967a\u56e0\u5b50\u3067\u3042\u308b\u3053\u3068\u3092\u652f\u6301\u3059\u308b\u30a8\u30d3\u30c7\u30f3\u30b9\u306f\u3042\u308b\u304c\u3001PAD\u60a3\u8005\u306b\u304a\u3051\u308bLp(a)\u306e\u4e0a\u6607\u3068\u305d\u306e\u5f8c\u306e\u5fc3\u8840\u7ba1\u7cfb\u304a\u3088\u3073\u56db\u80a2\u306e\u8ee2\u5e30\u3068\u306e\u95a2\u4fc2\u306f\u3042\u307e\u308a\u660e\u3089\u304b\u3067\u306f\u306a\u3044\u3002 <\/p>\n

 <\/p>\n

\u672c\u7814\u7a76\u306f\u3053\u306e\u7591\u554f\u306b\u53d6\u308a\u7d44\u307f\u3001Lp(a)\u6fc3\u5ea6\u306e\u4e0a\u6607\u304cPAD\u60a3\u8005\u306b\u304a\u3051\u308b\u5fc3\u8840\u7ba1\u30a4\u30d9\u30f3\u30c8\u304a\u3088\u3073\u4e0b\u80a2\u306e\u6709\u5bb3\u4e8b\u8c61\u306e\u767a\u75c7\u3068\u5f37\u304f\u95a2\u9023\u3057\u3066\u3044\u308b\u3053\u3068\u3092\u8a3c\u660e\u3057\u305f\u3002PAD\u60a3\u8005\u3067Lp(a)\u6fc3\u5ea6\u304c132\uff5e855nmol\/L\uff08\u56db\u5206\u4f4d\u65704\uff09\u306e\u5834\u5408\u3001Lp(a)\u6fc3\u5ea6\u304c14nmol\/L\u4ee5\u4e0b\u306e\u60a3\u8005\u3068\u6bd4\u8f03\u3057\u3066\u3001MACE\u767a\u75c7\u30ea\u30b9\u30af\u306f30\uff05\u9ad8\u304f\u3001MALE\u767a\u75c7\u30ea\u30b9\u30af\u306f19\uff05\u9ad8\u304b\u3063\u305f\u3002\u81e8\u5e8a\u7684\u306a\u610f\u601d\u6c7a\u5b9a\u306b\u304a\u3044\u3066\u300c\u30b0\u30ec\u30fc\u300d\u307e\u305f\u306f\u4e2d\u9593\u7684\u306aLp(a)\u6fc3\u5ea6\uff08\u3059\u306a\u308f\u3061\u300130\u301c50mg\/dL\uff1b75\u301c125nmol\/L\uff09\u306e\u7bc4\u56f2\u5185\u3068\u8003\u3048\u3089\u308c\u308b\u56db\u5206\u4f4d\u7fa43\uff0842\u301c<132nmol\/L\uff09\u306e\u60a3\u8005\u306b\u304a\u3044\u3066\u3082\uff081\uff09\u3001\u5076\u767a\u7684MACE\u306e\u30ea\u30b9\u30af\u306f24\uff05\u5897\u52a0\u3057\u305f\uff08p=0.005\uff09\u304c\u3001\u5076\u767a\u7684MALE\u306e\u30ea\u30b9\u30af\u306b\u306f\u6709\u610f\u306a\u5897\u52a0\u306f\u8a8d\u3081\u3089\u308c\u306a\u304b\u3063\u305f\u3002\u3057\u304b\u3057\u3001\u3053\u308c\u3089\u306e\u6240\u898b\u306f\u3001Lp(a)\u6fc3\u5ea6> 75\u30d1\u30fc\u30bb\u30f3\u30bf\u30a4\u30eb\u3067\u306e\u307fMALE\u30ea\u30b9\u30af\u306e\u5897\u52a0\u304c\u5831\u544a\u3055\u308c\u305f\u4ee5\u524d\u306e\u7814\u7a76\u3068\u4e00\u81f4\u3057\u3066\u3044\u308b(4)\u3002 <\/p>\n

 <\/p>\n

\u3053\u306e\u5b9f\u81e8\u5e8a\u30ec\u30b8\u30b9\u30c8\u30ea\u306f\u30ec\u30c8\u30ed\u30b9\u30da\u30af\u30c6\u30a3\u30d6\u3067\u3042\u308b\u306b\u3082\u304b\u304b\u308f\u3089\u305a\u3001\u7814\u7a76\u5bfe\u8c61\u96c6\u56e3\u306e\u5927\u304d\u3055\u3068\u8ffd\u8de1\u671f\u9593\u306e\u9577\u3055\u304c\u7814\u7a76\u306e\u4fe1\u983c\u6027\u3092\u9ad8\u3081\u3001\u6700\u3082\u30ea\u30b9\u30af\u306e\u9ad8\u3044PAD\u60a3\u8005\u3092\u540c\u5b9a\u3057\u3001\u305d\u308c\u306b\u5fdc\u3058\u3066\u6cbb\u7642\u3092\u5f37\u5316\u3059\u308b\u305f\u3081\u306bLp(a)\u3092\u6e2c\u5b9a\u3059\u308b\u7406\u8ad6\u7684\u6839\u62e0\u3092\u63d0\u4f9b\u3057\u3066\u3044\u308b\u3002PAD\u306f\u5e83\u304f\u8513\u5ef6\u3057\u3066\u304a\u308a(5,6)\u3001\u81e8\u5e8a\u7684\u5f8c\u907a\u75c7\u306f\u304b\u306a\u308a\u306e\u6b7b\u4ea1\u7387\u3001\u7f79\u60a3\u7387\u3001QOL\u306e\u4f4e\u4e0b\u3068\u95a2\u9023\u3057\u3066\u3044\u308b(7)\u3002 <\/p>\n

 <\/p>\n

\u53c2\u8003\u6587\u732e<\/strong><\/p>\n

    \n
  1. 1.Kronenberg F, Mora S, Stroes ESG, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement, Eur Heart J 2022;43: 3925-46. <\/li>\n
  2. Mach F, Koskinas KC, Roeters van Lennep JE, et al. 2025 Focused Update of the 2019 ESC\/EAS Guidelines for the management of dyslipidaemias\uff1a\u6b27\u5dde\u5fc3\u81d3\u75c5\u5b66\u4f1a\uff08ESC\uff09\u3068\u6b27\u5dde\u52d5\u8108\u786c\u5316\u5b66\u4f1a\uff08EAS\uff09\u306e\u8102\u8cea\u7570\u5e38\u75c7\u7ba1\u7406\u30bf\u30b9\u30af\u30d5\u30a9\u30fc\u30b9\u306b\u3088\u308a\u4f5c\u6210 Eur Heart J 2025; https:\/\/doi.org\/10.1093\/eurheartj\/ehaf190<\/a><\/li>\n
  3. Mach F, Baigent C, Catapano AL, et al. 2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).Eur Heart J 2020;41:111-88. <\/li>\n
  4. \u30ea\u30dd\u86cb\u767d\uff08a\uff09\u3001\u9178\u5316\u30ea\u30f3\u8102\u8cea\u3001\u51a0\u52d5\u8108\u5916\u8840\u7ba1\u75be\u60a3\u3068\u306e\u95a2\u9023\u3002J Lipid Res 2024;65:100585\u3002 <\/li>\n
  5. Varvel S\u3001McConnell JP\u3001Tsimikas S.\u7c73\u56fd\u306e532 359\u4eba\u306e\u60a3\u8005\u306b\u304a\u3051\u308bLp(a)\u8cea\u91cf\u5024\u4e0a\u6607\u306e\u6709\u75c5\u7387\u3068\u60a3\u8005\u306e\u95be\u5024\u3002Arterioscler Thromb Vasc Biol 2016; 36:2239-45. <\/li>\n
  6. Criqui MH, Matsushita K, Aboyans V, et al. \u4e0b\u80a2\u672b\u68a2\u52d5\u8108\u75be\u60a3\uff1a\u73fe\u4ee3\u306e\u75ab\u5b66\u3001\u7ba1\u7406\u30ae\u30e3\u30c3\u30d7\u3001\u5c06\u6765\u306e\u65b9\u5411\u6027\uff1a\u7c73\u56fd\u5fc3\u81d3\u5354\u4f1a\u304b\u3089\u306e\u79d1\u5b66\u7684\u58f0\u660e\u3002Circulation 2021;144:e171\u2013e191. <\/li>\n
  7. Kou T, Qian X, Liu Y, et al. \u672b\u68a2\u52d5\u8108\u75be\u60a3\u306e\u4e16\u754c\u7684\u3001\u5730\u57df\u7684\u3001\u56fd\u5bb6\u7684\u8ca0\u62c5\uff1a\u6709\u75c5\u7387\u3001\u767a\u75c7\u7387\u3001\u6b7b\u4ea1\u6570\u3001DALYs\u306e\u7cfb\u7d71\u7684\u5206\u6790\u3068\u4eca\u5f8c15\u5e74\u9593\u306e\u4e88\u6e2c\u3002Nutr Metab Cardiovasc Dis 2025\u5e747\u670811\u65e5\uff1a104226\u3002 <\/li>\n<\/ol>\n

    \u30ad\u30fc\u30ef\u30fc\u30c9\uff1a\u672b\u68a2\u52d5\u8108\u75be\u60a3\uff1b\u30ea\u30dd\u86cb\u767d\uff08a\uff09\uff1b\u767b\u9332\uff1bMACE\uff1b\u7537\u6027<\/em><\/p>\n

    [\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"

    \u30ea\u30dd\u30bf\u30f3\u30d1\u30af\u8cea(a)\u306e\u4e0a\u6607\uff1a\u672b\u68a2\u52d5\u8108\u75be\u60a3\u306b\u304a\u3051\u308b\u30ea\u30b9\u30af\u5897\u5f37\u56e0\u5b50 2025\u5e7410\u6708 Mass General B […]<\/p>\n","protected":false},"author":258497324,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"class_list":["post-257279","page","type-page","status-publish","hentry"],"yoast_head":"\nPAD\u306b\u304a\u3051\u308b\u30ea\u30b9\u30af\u5897\u5f37\u56e0\u5b50\u3068\u3057\u3066\u306eLp(a)\uff1aMass General Brigham Registry - R3i<\/title>\n<meta name=\"description\" content=\"Mass General Brigham Lp(a)\u30ec\u30b8\u30b9\u30c8\u30ea\u306e\u7d50\u679c\u304b\u3089\u3001\u30ea\u30dd\u86cb\u767d(a)\u306e\u4e0a\u6607\u306fPAD\u60a3\u8005\u306e\u5fc3\u8840\u7ba1\u30a4\u30d9\u30f3\u30c8\u3084\u56db\u80a2\u30a4\u30d9\u30f3\u30c8\u3068\u95a2\u9023\u3059\u308b\u3053\u3068\u304c\u793a\u3055\u308c\u305f\u3002\u30ea\u30b9\u30af\u5c64\u5225\u5316\u306e\u305f\u3081\u306eLp(a)\u306e\u4e88\u5f8c\u7684\u4fa1\u5024\u3092\u63a2\u308b\u3002\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/r3i.org\/ja\/focus-elevated-lipoproteina-a-risk-enhancer-in-peripheral-artery-disease\/\" \/>\n<meta property=\"og:locale\" content=\"ja_JP\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"PAD\u306b\u304a\u3051\u308b\u30ea\u30b9\u30af\u5897\u5f37\u56e0\u5b50\u3068\u3057\u3066\u306eLp(a)\uff1aMass General Brigham Registry - R3i\" \/>\n<meta property=\"og:description\" content=\"Mass General Brigham Lp(a)\u30ec\u30b8\u30b9\u30c8\u30ea\u306e\u7d50\u679c\u304b\u3089\u3001\u30ea\u30dd\u86cb\u767d(a)\u306e\u4e0a\u6607\u306fPAD\u60a3\u8005\u306e\u5fc3\u8840\u7ba1\u30a4\u30d9\u30f3\u30c8\u3084\u56db\u80a2\u30a4\u30d9\u30f3\u30c8\u3068\u95a2\u9023\u3059\u308b\u3053\u3068\u304c\u793a\u3055\u308c\u305f\u3002\u30ea\u30b9\u30af\u5c64\u5225\u5316\u306e\u305f\u3081\u306eLp(a)\u306e\u4e88\u5f8c\u7684\u4fa1\u5024\u3092\u63a2\u308b\u3002\" \/>\n<meta property=\"og:url\" content=\"https:\/\/r3i.org\/ja\/focus-elevated-lipoproteina-a-risk-enhancer-in-peripheral-artery-disease\/\" \/>\n<meta property=\"og:site_name\" content=\"R3I\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-04T20:28:00+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593\" \/>\n\t<meta name=\"twitter:data1\" content=\"2\u5206\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/r3i.org\\\/ja\\\/focus-elevated-lipoproteina-a-risk-enhancer-in-peripheral-artery-disease\\\/\",\"url\":\"https:\\\/\\\/r3i.org\\\/ja\\\/focus-elevated-lipoproteina-a-risk-enhancer-in-peripheral-artery-disease\\\/\",\"name\":\"PAD\u306b\u304a\u3051\u308b\u30ea\u30b9\u30af\u5897\u5f37\u56e0\u5b50\u3068\u3057\u3066\u306eLp(a)\uff1aMass General Brigham Registry - R3i\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/r3i.org\\\/ja\\\/#website\"},\"datePublished\":\"2025-11-07T08:50:26+00:00\",\"dateModified\":\"2026-03-04T20:28:00+00:00\",\"description\":\"Mass General Brigham Lp(a)\u30ec\u30b8\u30b9\u30c8\u30ea\u306e\u7d50\u679c\u304b\u3089\u3001\u30ea\u30dd\u86cb\u767d(a)\u306e\u4e0a\u6607\u306fPAD\u60a3\u8005\u306e\u5fc3\u8840\u7ba1\u30a4\u30d9\u30f3\u30c8\u3084\u56db\u80a2\u30a4\u30d9\u30f3\u30c8\u3068\u95a2\u9023\u3059\u308b\u3053\u3068\u304c\u793a\u3055\u308c\u305f\u3002\u30ea\u30b9\u30af\u5c64\u5225\u5316\u306e\u305f\u3081\u306eLp(a)\u306e\u4e88\u5f8c\u7684\u4fa1\u5024\u3092\u63a2\u308b\u3002\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/r3i.org\\\/ja\\\/focus-elevated-lipoproteina-a-risk-enhancer-in-peripheral-artery-disease\\\/#breadcrumb\"},\"inLanguage\":\"ja\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/r3i.org\\\/ja\\\/focus-elevated-lipoproteina-a-risk-enhancer-in-peripheral-artery-disease\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/r3i.org\\\/ja\\\/focus-elevated-lipoproteina-a-risk-enhancer-in-peripheral-artery-disease\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/r3i.org\\\/ja\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Focus \u2013 Elevated lipoprotein(a): a risk enhancer in peripheral artery disease\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/r3i.org\\\/ja\\\/#website\",\"url\":\"https:\\\/\\\/r3i.org\\\/ja\\\/\",\"name\":\"R3I\",\"description\":\"Residual Risk Reduction Initiative\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/r3i.org\\\/ja\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ja\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"PAD\u306b\u304a\u3051\u308b\u30ea\u30b9\u30af\u5897\u5f37\u56e0\u5b50\u3068\u3057\u3066\u306eLp(a)\uff1aMass General Brigham Registry - R3i","description":"Mass General Brigham Lp(a)\u30ec\u30b8\u30b9\u30c8\u30ea\u306e\u7d50\u679c\u304b\u3089\u3001\u30ea\u30dd\u86cb\u767d(a)\u306e\u4e0a\u6607\u306fPAD\u60a3\u8005\u306e\u5fc3\u8840\u7ba1\u30a4\u30d9\u30f3\u30c8\u3084\u56db\u80a2\u30a4\u30d9\u30f3\u30c8\u3068\u95a2\u9023\u3059\u308b\u3053\u3068\u304c\u793a\u3055\u308c\u305f\u3002\u30ea\u30b9\u30af\u5c64\u5225\u5316\u306e\u305f\u3081\u306eLp(a)\u306e\u4e88\u5f8c\u7684\u4fa1\u5024\u3092\u63a2\u308b\u3002","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/r3i.org\/ja\/focus-elevated-lipoproteina-a-risk-enhancer-in-peripheral-artery-disease\/","og_locale":"ja_JP","og_type":"article","og_title":"PAD\u306b\u304a\u3051\u308b\u30ea\u30b9\u30af\u5897\u5f37\u56e0\u5b50\u3068\u3057\u3066\u306eLp(a)\uff1aMass General Brigham Registry - R3i","og_description":"Mass General Brigham Lp(a)\u30ec\u30b8\u30b9\u30c8\u30ea\u306e\u7d50\u679c\u304b\u3089\u3001\u30ea\u30dd\u86cb\u767d(a)\u306e\u4e0a\u6607\u306fPAD\u60a3\u8005\u306e\u5fc3\u8840\u7ba1\u30a4\u30d9\u30f3\u30c8\u3084\u56db\u80a2\u30a4\u30d9\u30f3\u30c8\u3068\u95a2\u9023\u3059\u308b\u3053\u3068\u304c\u793a\u3055\u308c\u305f\u3002\u30ea\u30b9\u30af\u5c64\u5225\u5316\u306e\u305f\u3081\u306eLp(a)\u306e\u4e88\u5f8c\u7684\u4fa1\u5024\u3092\u63a2\u308b\u3002","og_url":"https:\/\/r3i.org\/ja\/focus-elevated-lipoproteina-a-risk-enhancer-in-peripheral-artery-disease\/","og_site_name":"R3I","article_modified_time":"2026-03-04T20:28:00+00:00","twitter_card":"summary_large_image","twitter_misc":{"\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593":"2\u5206"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/r3i.org\/ja\/focus-elevated-lipoproteina-a-risk-enhancer-in-peripheral-artery-disease\/","url":"https:\/\/r3i.org\/ja\/focus-elevated-lipoproteina-a-risk-enhancer-in-peripheral-artery-disease\/","name":"PAD\u306b\u304a\u3051\u308b\u30ea\u30b9\u30af\u5897\u5f37\u56e0\u5b50\u3068\u3057\u3066\u306eLp(a)\uff1aMass General Brigham Registry - R3i","isPartOf":{"@id":"https:\/\/r3i.org\/ja\/#website"},"datePublished":"2025-11-07T08:50:26+00:00","dateModified":"2026-03-04T20:28:00+00:00","description":"Mass General Brigham Lp(a)\u30ec\u30b8\u30b9\u30c8\u30ea\u306e\u7d50\u679c\u304b\u3089\u3001\u30ea\u30dd\u86cb\u767d(a)\u306e\u4e0a\u6607\u306fPAD\u60a3\u8005\u306e\u5fc3\u8840\u7ba1\u30a4\u30d9\u30f3\u30c8\u3084\u56db\u80a2\u30a4\u30d9\u30f3\u30c8\u3068\u95a2\u9023\u3059\u308b\u3053\u3068\u304c\u793a\u3055\u308c\u305f\u3002\u30ea\u30b9\u30af\u5c64\u5225\u5316\u306e\u305f\u3081\u306eLp(a)\u306e\u4e88\u5f8c\u7684\u4fa1\u5024\u3092\u63a2\u308b\u3002","breadcrumb":{"@id":"https:\/\/r3i.org\/ja\/focus-elevated-lipoproteina-a-risk-enhancer-in-peripheral-artery-disease\/#breadcrumb"},"inLanguage":"ja","potentialAction":[{"@type":"ReadAction","target":["https:\/\/r3i.org\/ja\/focus-elevated-lipoproteina-a-risk-enhancer-in-peripheral-artery-disease\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/r3i.org\/ja\/focus-elevated-lipoproteina-a-risk-enhancer-in-peripheral-artery-disease\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/r3i.org\/ja\/"},{"@type":"ListItem","position":2,"name":"Focus \u2013 Elevated lipoprotein(a): a risk enhancer in peripheral artery disease"}]},{"@type":"WebSite","@id":"https:\/\/r3i.org\/ja\/#website","url":"https:\/\/r3i.org\/ja\/","name":"R3I","description":"Residual Risk Reduction Initiative","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/r3i.org\/ja\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ja"}]}},"jetpack_likes_enabled":true,"jetpack_sharing_enabled":true,"jetpack_shortlink":"https:\/\/wp.me\/Pgbfv2-14VF","jetpack-related-posts":[],"_links":{"self":[{"href":"https:\/\/r3i.org\/ja\/wp-json\/wp\/v2\/pages\/257279","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/r3i.org\/ja\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/r3i.org\/ja\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/r3i.org\/ja\/wp-json\/wp\/v2\/users\/258497324"}],"replies":[{"embeddable":true,"href":"https:\/\/r3i.org\/ja\/wp-json\/wp\/v2\/comments?post=257279"}],"version-history":[{"count":4,"href":"https:\/\/r3i.org\/ja\/wp-json\/wp\/v2\/pages\/257279\/revisions"}],"predecessor-version":[{"id":257283,"href":"https:\/\/r3i.org\/ja\/wp-json\/wp\/v2\/pages\/257279\/revisions\/257283"}],"wp:attachment":[{"href":"https:\/\/r3i.org\/ja\/wp-json\/wp\/v2\/media?parent=257279"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}